Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
arcticnovartis
- New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1
- Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of kidney function – vs. patients’ historic rapid decline1
- Fabhalta also showed a favorable safety profile with no new safety signals1